Sidoti Csr Has Optimistic Outlook of Kamada FY2025 Earnings

Kamada Ltd. (NASDAQ:KMDA) – Research analysts at Sidoti Csr lifted their FY2025 earnings per share (EPS) estimates for Kamada in a report released on Wednesday, May 14th. Sidoti Csr analyst J. Sidoti now expects that the biotechnology company will post earnings of $0.28 per share for the year, up from their prior estimate of $0.27. The consensus estimate for Kamada’s current full-year earnings is $0.23 per share.

A number of other equities analysts have also recently weighed in on KMDA. Sidoti raised Kamada to a “hold” rating in a report on Thursday, May 8th. Benchmark reissued a “buy” rating and issued a $15.00 price target on shares of Kamada in a report on Thursday. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Kamada in a report on Thursday, March 6th. Finally, StockNews.com cut Kamada from a “strong-buy” rating to a “buy” rating in a report on Tuesday, March 25th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Kamada presently has an average rating of “Moderate Buy” and a consensus price target of $14.67.

Kamada Stock Performance

KMDA opened at $6.94 on Friday. The business’s fifty day moving average is $6.60 and its two-hundred day moving average is $6.60. The company has a market cap of $398.91 million, a price-to-earnings ratio of 24.79, a PEG ratio of 0.97 and a beta of 0.94. Kamada has a one year low of $4.74 and a one year high of $9.16.

Kamada (NASDAQ:KMDA) last posted its earnings results on Wednesday, May 14th. The biotechnology company reported $0.07 EPS for the quarter, hitting analysts’ consensus estimates of $0.07. The company had revenue of $44.02 million for the quarter, compared to the consensus estimate of $154.06 million. Kamada had a return on equity of 6.30% and a net margin of 9.92%.

Hedge Funds Weigh In On Kamada

Several institutional investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. acquired a new position in Kamada in the first quarter valued at $497,000. NewEdge Advisors LLC increased its stake in Kamada by 119.9% in the first quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company’s stock valued at $341,000 after purchasing an additional 28,165 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in Kamada in the first quarter valued at $206,000. Trexquant Investment LP acquired a new stake in Kamada during the first quarter worth about $82,000. Finally, Huntleigh Advisors Inc. acquired a new stake in Kamada during the first quarter worth about $863,000. 20.38% of the stock is currently owned by institutional investors and hedge funds.

Kamada Dividend Announcement

The firm also recently announced a — dividend, which was paid on Monday, April 7th. Investors of record on Monday, March 17th were paid a $0.20 dividend. The ex-dividend date was Monday, March 17th.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.